⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for Multicenter Study of Hypofractionated Postoperative Radiotherapy in Patients Diagnosed With Prostate Carcinoma

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Multicenter Study of Hypofractionated Postoperative Radiotherapy in Patients Diagnosed With Prostate Carcinoma

Official Title: Multicenter Study of Hypofractionated Postoperative Radiotherapy in Patients Diagnosed With Prostate Carcinoma

Study ID: NCT04484038

Conditions

Prostate Cancer

Study Description

Brief Summary: The objective of this study is to evaluate, in patients diagnosed with prostate cancer who undergo radical prostatectomy and who require postoperative radiotherapy, tolerance in terms of acute and chronic GU and GI toxicity and efficacy in terms of biochemical control and survival, as well as of quality of life, from a hypofractional external radiotherapy scheme, increasing the dose per fraction in a shorter period of time.

Detailed Description: What the investigators present in this study is a hypofractionation scheme of 62.5 Gy in 25 daily fractions of 2.5 Gy / day, which was chosen to provide a biological equivalent dose (BED) of 166.67 Gy, comparable to the 163 Gy administered with a scheme Normally divided up to 70 Gy in daily fractions of 2 Gy / day Version 2.0, March 27, 2019 (assuming an α / β ratio of 1.5 Gy for prostate cancer). The BED in risk organs (mainly rectum and bladder) will be governed by the ratio used and will differ depending on whether acute or late toxicity is calculated. If selected an acute α / β of 10 Gy and a conservative α / β for late toxicity of 3 Gy, the standard fractionation will result in an acute BED of 84 Gy versus 78 Gy in the hypofractionation scheme and a BED of 116.67 vs. 114.5 Gy for late toxicity. Therefore, what the investigators expect is a toxicity profile that is at least similar, if not slightly better, compared to the norm-fractionated scheme of 70 Gy in 35 fractions and similar rates of biochemical control and survival. To all this is added the use of intensity modulated radiotherapy and image-guided radiotherapy techniques (IGRT) that will allow the investigators to significantly reduce the dose administered to risk organs.

Eligibility

Minimum Age: 18 Years

Eligible Ages: ADULT, OLDER_ADULT

Sex: MALE

Healthy Volunteers: No

Locations

Hospital General Gregorio Marañón, Madrid, Adrid, Spain

Hospital Universitario de San Juan, San Juan, Alicante, Spain

ICO Badalona, Badalona, Barcelona, Spain

Hospital Dr. Negrin, Las Palmas de Gran Canaria, Gran Canaria, Spain

Hospital Universitario de Santiago, Santiago de Compostela, La Coruña, Spain

Hospital de Fuenlabrada, Fuenlabrada, Madrid, Spain

Hospital Universitario Torrecárdenas, Almería, , Spain

Hospital Universitario de Badajoz, Badajoz, , Spain

H. Sta. Cruz y San Pablo, Barcelona, , Spain

Instituto Oncológico IMQ, Bilbao, , Spain

Hospital Universitario San Cecilio, Granada, , Spain

Hospital Universitario Ramón Y Cajal, Madrid, , Spain

Fundación Jimenez Díaz 1, Madrid, , Spain

Fundación Jiménez Díaz 2, Madrid, , Spain

Hospital de La Princesa, Madrid, , Spain

Hospital La Luz, Madrid, , Spain

Hospital Quirón, Madrid, , Spain

Hospital Ruber Internacional, Madrid, , Spain

Complejo Hospitalario de Navarra, Pamplona, , Spain

Contact Details

Name: ASUNCION R HERVAS, I

Affiliation: Ramon y Cajal University Hospital

Role: PRINCIPAL_INVESTIGATOR

Useful links and downloads for this trial

Clinicaltrials.gov

Google Search Results

Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: